-
Merger to Form Programmable Nano-Medicines Company
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties.
-
Coalition to Boost African Ancestry Genomic Data
An historically Black medical college and pharmaceutical industry group began a program to increase the numbers of people of African descent in genomic databases.
-
Organ Chip Devices to Model for Radiation Sickness
The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness.
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
High-Speed Biologic Injection Device Shown Feasible
A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes.
-
Infographic – Q3 Life Science Venture Funds Tick Up
Venture investments in U.S. life science and biotechnology start-ups in the third quarter of 2023 rose from the previous two quarters to reach pre-pandemic levels.
-
Botox Vs Dysport: Similarities And Difference
It is essential for aesthetic practitioners to remain aware of the non-bioequivalency of these formulations and to exercise caution against direct dose conversions.
-
Genetic Tests of Breast Cancer Patients Shown Useful
Experiences from a rural hospital in North Carolina show hereditary genetic testing of all breast cancer patients is feasible and can result in changes in care for many patients.
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
Collapsed Microbiome Biotech Sells Off Assets
A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program.